Clinical Trial

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-14
Trial Details
NCT Number NCT07570823
Lead Sponsor Sinocelltech Ltd.
Conditions DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 101 participants
Start Date 2026-06-04
Primary Completion 2027-11 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-13